---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009141"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:10:53.210061+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q1 net loss $23.9M; IND for MRT-2359 expected mid-2022

## Summary
- Net loss $23.9M for Q1 2022 vs $12.3M in Q1 2021; R&D spend $17.9M.
- Cash position $322.5M as of March 31, 2022; runway into late 2024.
- IND submission for GSPT1 degrader MRT-2359 on track for mid-2022; initial focus on NSCLC and SCLC.
- Preclinical data at AACR 2022 support MRT-2359 in Myc-driven solid tumors.
- New collaboration with EPFL to integrate AI engine with MaSIF technology for novel degrader discovery.

## SEC filing metadata
- accession: 0000950170-22-009141
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017022009141/0000950170-22-009141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017022009141/glue-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009141
- JSON: https://secwatch.observer/filing/0000950170-22-009141.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.